Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B

Table 1 Exploratory variables used in the multivariate analyses

Class	Study value
Treatment group	Micafungin 100 mg/day
	Liposomal amphotericin B 3 mg/kg/day
Age (years)	Continuous
Sex	Female
	Male
Region	Brazil, Europe, India, North America
	Other
Race	Caucasian
	Asian-Indian
	Black
	Other
Primary diagnosis	Candidemia
	Disseminated candidiasis
Organism	Candida albicans only versus non-albicans Candida
	C. albicans, Candida tropicalis, Candida parapsilosis, Candida glabrata versus other Candida spp.
	Candida parapsilosis versus other Candida spp.
	Candida krusei versus other Candida spp.
Neutropenia^a at baseline	Yes/No
Persistent neutropenia	Yes/No
Liver disorder/failure	Yes/No
Renal disorder/failure	Yes/No
Antibiotic use	Yes/No
Diabetes mellitus	Yes/No
Solid organ transplant	Yes/No
Corticosteroid therapy	Yes/No
Catheter status^b	Removed within 48 hours of treatment initiation, Yes/No
	Removed at any time during the study, Yes/No
Acute Physiology and Chronic Health Evaluation II score	Continuous

^aAbsolute neutrophil count < 500 cells/μl. ^bExplanatory variable used in analysis of candidemic patients only.

ISSN: 1364-8535